JP2024521131A5 - - Google Patents
Info
- Publication number
- JP2024521131A5 JP2024521131A5 JP2023572165A JP2023572165A JP2024521131A5 JP 2024521131 A5 JP2024521131 A5 JP 2024521131A5 JP 2023572165 A JP2023572165 A JP 2023572165A JP 2023572165 A JP2023572165 A JP 2023572165A JP 2024521131 A5 JP2024521131 A5 JP 2024521131A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- antibody
- human
- binding
- polypeptide according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163192549P | 2021-05-24 | 2021-05-24 | |
| US63/192,549 | 2021-05-24 | ||
| US202163265032P | 2021-12-06 | 2021-12-06 | |
| US63/265,032 | 2021-12-06 | ||
| US202263266453P | 2022-01-05 | 2022-01-05 | |
| US63/266,453 | 2022-01-05 | ||
| PCT/US2022/030556 WO2022251119A2 (en) | 2021-05-24 | 2022-05-23 | Engineered polypeptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024521131A JP2024521131A (ja) | 2024-05-28 |
| JP2024521131A5 true JP2024521131A5 (cg-RX-API-DMAC7.html) | 2025-07-03 |
Family
ID=82156443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023572165A Pending JP2024521131A (ja) | 2021-05-24 | 2022-05-23 | 操作されたポリペプチド |
Country Status (13)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3183367A1 (en) | 2020-07-06 | 2022-01-13 | Gevorg GRIGORYAN | Antigen binding molecules targeting sars-cov-2 |
| CA3183373A1 (en) | 2020-07-06 | 2022-01-13 | Gevorg GRIGORYAN | Antigen binding molecules targeting sars-cov-2 |
| KR20230058434A (ko) | 2020-08-26 | 2023-05-03 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | SARS-CoV-2를 표적으로 하는 항원 결합 분자 |
| WO2023230439A1 (en) | 2022-05-23 | 2023-11-30 | Vir Biotechnology, Inc. | Fc-engineered hepatitis b virus neutralizing antibodies and uses thereof |
| WO2023245078A1 (en) | 2022-06-15 | 2023-12-21 | Humabs Biomed Sa | Anti-parvovirus antibodies and uses thereof |
| WO2024006472A1 (en) | 2022-06-30 | 2024-01-04 | Vir Biotechnology, Inc. | Antibodies that bind to multiple sarbecoviruses |
| JP2025526405A (ja) | 2022-07-27 | 2025-08-13 | ヒューマブス・バイオメッド・ソシエテ・アノニム | Rsv及びmpvパラミクソウイルスに対する広域中和抗体 |
| WO2024182781A1 (en) | 2023-03-02 | 2024-09-06 | Vir Biotechnology, Inc. | Coronavirus compositions and uses thereof |
| TW202446788A (zh) | 2023-04-10 | 2024-12-01 | 美商維爾生物科技公司 | 結合多種薩貝冠狀病毒之抗體 |
| WO2025010424A1 (en) | 2023-07-06 | 2025-01-09 | Vir Biotechnology, Inc. | Antibodies against staphylococcus antigens and methods of using the same |
| EP4743488A1 (en) | 2023-07-13 | 2026-05-20 | VIR Biotechnology, Inc. | Antibodies widely neutralizing against paramyxoviruses RSV and MPV |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| WO2004076677A2 (en) | 2003-02-26 | 2004-09-10 | Institute For Research In Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| WO2005028515A1 (ja) | 2003-09-24 | 2005-03-31 | Kyowa Hakko Kogyo Co., Ltd. | ヒトインスリン様成長因子に対する遺伝子組換え抗体 |
| US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| WO2008042814A2 (en) | 2006-09-29 | 2008-04-10 | California Institute Of Technology | Mart-1 t cell receptors |
| WO2010033279A2 (en) * | 2008-06-04 | 2010-03-25 | Macrogenics, Inc. | Antibodies with altered binding to fcrn and methods of using same |
| CN103261222B (zh) | 2010-09-10 | 2017-07-28 | 医疗免疫有限公司 | 抗体衍生物 |
| US9663581B2 (en) | 2012-04-25 | 2017-05-30 | Momenta Pharmaceuticals, Inc. | Modified glycoproteins |
| AU2014374055B2 (en) | 2013-12-30 | 2018-11-08 | Epimab Biotherapeutics Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| US20160257761A1 (en) * | 2015-03-06 | 2016-09-08 | Macrogenics, Inc. | HER2/neu-Specific Antibodies and Methods of Using Same |
| US11267899B2 (en) | 2015-05-13 | 2022-03-08 | Zumutor Biologics Inc. | Afucosylated protein, cell expressing said protein and associated methods |
| US20200157192A1 (en) * | 2017-05-10 | 2020-05-21 | Albajuna Therapeutics, S.L. | Fc-fusion protein derivatives with high dual hiv antiviral and immunomodulatory activity |
| WO2019024979A1 (en) | 2017-07-31 | 2019-02-07 | Institute For Research In Biomedicine | FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION |
| CN117843810A (zh) | 2017-09-22 | 2024-04-09 | 上海药明生物技术有限公司 | 新型双特异性多肽复合物 |
| JP7351845B2 (ja) * | 2018-03-23 | 2023-09-27 | ブリストル-マイヤーズ スクイブ カンパニー | Micaおよび/またはmicbに対する抗体ならびにそれらの使用 |
| US20220298230A1 (en) * | 2019-06-11 | 2022-09-22 | The Rockefeller University | Antibodies and methods for treatment of viral infections |
-
2022
- 2022-05-23 KR KR1020237044483A patent/KR20240035758A/ko active Pending
- 2022-05-23 TW TW111119113A patent/TW202306978A/zh unknown
- 2022-05-23 BR BR112023024494A patent/BR112023024494A2/pt unknown
- 2022-05-23 CA CA3218489A patent/CA3218489A1/en active Pending
- 2022-05-23 JP JP2023572165A patent/JP2024521131A/ja active Pending
- 2022-05-23 MX MX2023013859A patent/MX2023013859A/es unknown
- 2022-05-23 AU AU2022280767A patent/AU2022280767A1/en active Pending
- 2022-05-23 IL IL308509A patent/IL308509A/en unknown
- 2022-05-23 WO PCT/US2022/030556 patent/WO2022251119A2/en not_active Ceased
- 2022-05-23 US US18/563,674 patent/US20250296986A1/en active Pending
- 2022-05-23 EP EP22732744.2A patent/EP4347642A2/en active Pending
-
2023
- 2023-11-21 CL CL2023003455A patent/CL2023003455A1/es unknown
- 2023-12-19 CO CONC2023/0017754A patent/CO2023017754A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7857273B2 (ja) | Cd3および腫瘍抗原に結合するヘテロ二量体抗体 | |
| US11377477B2 (en) | PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof | |
| US11505595B2 (en) | TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains | |
| US12509495B2 (en) | LAG-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and LAG-3 antigen binding domains | |
| US20240294593A1 (en) | Pd-1 targeted il-15/il-15ralpha fc fusion proteins with improved properties | |
| JP7021127B2 (ja) | ソマトスタチン受容体2に結合するヘテロ二量体抗体 | |
| JP7328761B2 (ja) | 多価多重特異性ox40結合融合タンパク質 | |
| US11584794B2 (en) | Bispecific heterodimeric fusion proteins containing IL-15-IL-15Ralpha Fc-fusion proteins and immune checkpoint antibody fragments | |
| AU2016262368B2 (en) | Heterodimeric antibodies that bind CD3 and tumor antigens | |
| JP7178342B2 (ja) | アゴニズム及びエフェクター機能が増強した改変抗体、及び他のFcドメイン含有分子 | |
| JP7010854B2 (ja) | 二重特異性チェックポイント阻害剤抗体 | |
| US20220227867A1 (en) | ICOS TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND ICOS ANTIGEN BINDING DOMAINS | |
| CN119365490A (zh) | 结合pd-l1、pd-l2和/或cd28的抗体 | |
| US20250043001A1 (en) | Anti-cd28 compositions | |
| US20240392025A1 (en) | B-cell maturation antigen (bcma) binding domain compositions | |
| HK40093127A (en) | Heterodimeric antibodies that bind cd3 and tumor antigens | |
| HK40065611A (en) | Heterodimeric antibodies that bind cd3 and tumor antigens | |
| EA044325B1 (ru) | ГЕТЕРОДИМЕРНОЕ АНТИ-CD3xCD20 АНТИТЕЛО, ЕГО ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ |